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Background: Polymorphism among class I molecules of
the major histocompatibility complex (MHC) confers
allotypic specificity on the peptides that these molecules
bind and present to cytotoxic T lymphocytes. Evolution
of new human HLA class I alleles usually involves gene
recombination events that replace a segment of one allele
with the homologous region of another. In this study, the
impact of these evolutionary changes has been assessed by
comparison of the peptide-binding specificities of six
related HLA-B allotypes.
Results: Endogenous peptides bound by HLA-B*5401,
HLA-B*5501, HLA-B*5502, HLA-B*5601, HLA-
B*6701 and HLA-B*0702 were characterized. Despite
differing by 1-9 of the amino-acid residues comprising
their peptide-binding sites, all these allotypes share a
dominant preference for peptides that have proline at
position 2. Polymorphism results in differing selection of
carboxy-terminal and secondary anchor residues, but the
peptide-binding specificities are sufficiently similar that
there is overlap in the repertoires of peptides bound by
these allotypes. Complete sequence determination of
individual peptides revealed four that could be isolated
from two or more allotypes. Members of the closely
related HLA-B22 family - HLA-B*5401, HLA-
B*5501, HLA-B*5502 and HLA-B*5601 - show only
minor differences in their peptide-binding specificities.
This marked similarity is reflected at the functional level,
as alloreactive cytotoxic T lymphocytes generated
against HLA-B*5401 and HLA-B*5501 exhibited cross-
reactive recognition.
Conclusion: The isolation of identical endogenously
bound peptides from six HLA-B allotypes demonstrates
overlap in the repertoires of peptides bound in vivo by
different allotypes. We speculate that the shared prefer-
ence for binding peptides with proline at position 2
reflects a selective pressure to retain this specificity, which
may be based upon peptide availability in vivo. Charac-
terization of the overlap between the repertoires of
peptides bound by HLA-B allotypes could simplify the
development of peptide-based vaccines that are targeted
to cytotoxic T cells, as single peptides would be effective
for humans of different HLA types.
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Background
Class I molecules of the major histocompatibility com-
plex (MHC) are polymorphic glycoproteins that bind
peptides and present them to cytotoxic T lymphocytes;
they also regulate cell lysis by natural killer lymphocytes.
Both cytotoxic T cells and natural killer cells provide
defence against cells infected with intracellular parasites,
including viruses, or cells that have undergone malignant
transformation. Class I proteins comprise a polymorphic
class I heavy chain non-covalently associated with 32-
microglobulin. The oti and or2 domains of the class I
heavy chain form a binding site which is occupied by a
single peptide, usually nine amino acids long. Although
peptides of diverse amino-acid sequence can be bound
by a single class I allotype, each allotype binds a defined
repertoire of peptides that share a sequence motif
(reviewed in [1]), with motifs comprising one-or two
conserved positions known as anchors. Variation at the
other positions allows binding of many thousands of
different peptides by a single allotype [2].
Motifs can be deduced by sequence analysis of peptide
pools [3] or by alignment of individual peptides bound
by a given allotype [4,5]. Studies to date show that, for
peptides bound by products of the HLA-A and HLA-B
human class I MHC loci, anchor residues at position 2
and the carboxyl terminus predominate. Amino-acid
preferences at anchor positions are characteristic of each
class I allotype, and the crystal structures of HLA mol-
ecules show that specificity results from complementary
interactions with polymorphic subsites, or pockets, in the
peptide-binding site [6-8]. As differences between alleles
focus on residues that line the peptide-binding site, the
current view is that polymorphism serves to change the
repertoire of peptides bound. Class I polymorphism is
relatively even within human populations, such that there
are no dominant allotypes. So far, 50 HLA-A, 97 HLA-B
and 34 HLA-C alleles, obtained from a range of ethnic
groups, have been identified [9]. But the extent to which
each allele's product binds a unique repertoire of peptides
has yet to be assessed.
Experiments using various assay systems in vitro have sug-
gested that binding of peptide to class I molecules is pre-
dominantly allotype-specific [10-12]. The paucity of
peptides binding to more than one allotype reflects dras-
tic differences in the peptide anchor residues preferred by
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different allotypes. For example, HLA-A*0201 selects
peptides with leucine at position 2 [3], whereas HLA-
B*2705 prefers those with arginine at this position [4].
Even the closely related HLA-A*0201 and HLA-A*0205
allotypes, which differ only at four amino-acid residues,
exhibit substantial differences in their bound-peptide
motifs [13]. There are, however, reports of synthetic pep-
tides binding to more than one allotype. Examples of
HLA-A*0201-binding peptides binding also to other
HLA-A allotypes have been described [14]. Certain pep-
tides bound by HLA-A3 can also bind to HLA-A11 [15],
whereas others bind to HLA-A1 [16], and screening for
potential T-cell epitopes in malaria parasite proteins
revealed many peptides that bind both HLA-B*5301 and
HLA-B*5101 [17]. Of particular note, peptides able to
bind both HLA-B*2705 and HLA-A3, two molecules
with divergent sequences that are products of different
loci, have been described [12,18].
New class I alleles arise primarily as a result of re-assort-
ment of gene segments from existing alleles, rather than by
acquisition of unique substitutions [19]. As sequence vari-
ation is concentrated within the peptide-binding site,
products of recombinant class I alleles might be expected
to have recombined peptide-binding specificities. To in-
vestigate this hypothesis, we examined the peptide-binding
preferences of six serologically cross-reactive HLA-B allo-
types that differ in pair-wise comparison by 1-17 positions
in their al and or2 domains (Fig. 1). HLA-B*5401 and
HLA-B*5502 (found mainly in oriental populations), and
HLA-B*5501 and HLA-B*5601 (found at highest fre-
quency in Caucasians), are members of a closely related
family called HLA-B22. These four subtypes probably
evolved one from another by a series of simple gene re-
combinations [20], each of which introduces one or two
residue changes (Fig. 1 and highlighted residues in Fig. 2)
within the peptide-binding site. Forty of the HLA-B alle-
les defined so far were probably formed by recombinations
analogous to those seen in the HLA-B22 family [21].
In this study, the endogenous peptides bound by HLA-
B*5401, HLA-B*5501, HLA-B*5502, HLA-B*5601,
Fig. 1. A pair-wise comparison of HLA-B*0702, HLA-B*5401,
HLA-B*5501, HLA-B*5502, HLA-B*5601 and HLA-B*6701, indi-
cating the total number of residues that differ between their 1
and c2 domains. Comparisons between members of the HLA-
B22 family are shown within the blue triangle.
HLA-B*6701 and HLA-B*0702 have been characterized.
Comparison of the peptide-binding specificities of HLA-
B*5401, HLA-B*5501, HLA-B*5502 and HLA-B*5601
allowed us to assess the functional impact of small changes
typical of those acquired during the evolution of new
alleles. Inclusion of HLA-B*0702 and HLA-B*6701 in
the panel of allotypes studied allowed the effects of more
drastic sequence differences on peptide-binding specificity
to be assessed. The common feature of these six allotypes
is an identical a-helix in the al domain (residues 57-84).
For HLA-B*0702 and HLA-B*6701, sequence identity
extends throughout the al domain [22]. These two allo-
types differ, however, at eleven positions in their a2
domains [22], six of which contribute to formation of the
peptide-binding site (Fig. 2). HLA-B*0702 is a common
allotype present in African, European and Asian popula-
tions. In contrast, HLA-B*6701 is rare and confined
mainly to oriental populations. Our results have potential
clinical implications, as well as shedding light on the
evolution of HLA class I alleles.
Results
Characterization of peptide-binding motifs reveals a shared
preference for proline at position 2
In our experiments, we exploited the specificity of the
ME1 monoclonal antibody [23] for HLA-B molecules
that have either alanine-glutamine-alanine or alanine-
lysine-alanine at positions 69-71 of their aol helix.
Expression of the ME1 epitope by members of the HLA-
B22 family and by HLA-B*0702 and HLA-B*6701
(indicated in Fig. 2) [22,23] enabled us to purify these
molecules from cell lines derived from heterozygous
individuals.
Peptide specificities were determined by sequencing pools
of endogenously bound peptides eluted from purified
class I molecules. Peptide pools were subjected to 14
cycles of Edman-degradation sequencing. Experiments
were repeated at least twice, and, to prevent possible cont-
amination between peptides derived from different allo-
types, separate batches of ME1 antibody were used to
purify each allotype. Representative results are shown in
Table 1. No significant phenylthiohydantoin (PTH)
amino-acid signals were detected in cycles 10-14, so most
peptides are nine amino acids or fewer in length. Results
of the pool sequence analysis are summarized in Table 2.
The most striking feature of the peptide motifs defined
by this analysis is that, for all six allotypes, the dominant
anchor residue is proline at position 2 (numbered in rela-
tion to the amino terminus). No other positions were so
completely dominated by a single amino acid. Position 9,
the carboxyl terminus of the peptide, was the only other
position for which increases in just one or two amino
acids were observed, and here allotypic differences were
evident. The more divergent allotypes, HLA-B*0702
and HLA-B*6701, prefer leucine, whereas members of
the HLA-B22 family - HLA-B*5401, HLA-B*5501,
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Fig. 2. Comparison of the amino-acid sequences of the extracellular domains (al, ox2 and 3) of the class I heavy chains of
HLA-B*0702, HLA-B*6701, HLA-B*5401, HLA-B*5501, HLA-B*5502 and HLA-B*5601. Dashes indicate identity to HLA-B*0702.
Polymorphic positions within the B22 family members are highlighted in blue. Those polymorphic positions that contribute to forma-
tion of the peptide-binding site are indicated by black triangles (). The location of the epitope recognized by the ME1 monoclonal
antibody is indicated by ***
HLA-B*5502 and HLA-B*5601 - favour alanine. Some
of the HLA-B22-bound peptides may be octamers,
because the signal for alanine began to increase at posi-
tion 8 (Table 1). Thus the dominant anchor residues in
the peptides bound by the six allotypes examined in this
study are found at position 2 and the carboxyl terminus.
For peptide positions other than 2 and 9, increases in
many amino acids were observed. Some conservation at
positions I and 3 was noted, however, suggesting these
sites may represent secondary anchors. Increases in argi-
nine, methionine, tyrosine and phenylalanine were seen
consistently at position 3 of the peptides bound by HLA-
B*0702, HLA-B*5401, HLA-B*5501, HLA-B*5502
and HLA-B*5601. A distinguishing characteristic of the
HLA-B*6701 peptide pool was absence of the positively
charged amino acids, arginine and lysine, at position 3.
Residue preferences at position 1 were difficult to assess
because comparison with previous cycles was not possi-
ble and free amino acids present in some samples raised
the non-specific background. But comparison of the
yields for each amino acid in cycle 1 suggested that some
selection may occur at position 1. For all allotypes except
HLA-B*5401, alanine consistently formed more than
20 % of the total yield at cycle 1. For HLA-B*5401,
weak preferences for methionine and phenylalanine were
indicated: these residues generated 17 % and 7 %, respec-
tively, of the total signal at position 1 (values of 11 % and
12 %, respectively, were obtained in a repeat experiment;
data not shown). For the other allotypes, methionine and
phenylalanine never constituted more than 5 % and 3 %,
respectively, of the yields obtained in cycle 1.
Characterization of individual peptides reveals overlapping
repertoires of endogenously bound peptides
Sequence analysis of pools of peptides bound by class I
molecules reveals the dominant peptide-binding motif.
To gain further knowledge of the types of peptide bound,
individual sequences present in well-resolved peaks from
reverse-phase high performance liquid chromatography
(HPLC) separations were analysed by Edman degrada-
tion. Sequences were confirmed by analysis of peptide
molecular weights. The results obtained from peptides
associated with HLA-B*0702, HLA-B*5501, HLA-
B*5502 and HLA-B*5601 are shown in Table 3.
Individual sequences confirmed the peptide-binding
motifs defined by pool sequence analysis. Most peptides
were nonamers, with the exception of one peptide
bound by HLA-B*0702 which was a decamer. In most
cases, dominant anchors identified by pool sequence
analysis at positions 2 and 9 were present. Some addi-
tional residue preferences were also revealed, however.
Although pool sequencing identified a preference for
leucine at the carboxyl terminus of HLA-B*0702-bound
peptides, sequences of individual peptides showed that
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alanine and valine are also tolerated. This indicates that a
subset of HLA-B*0702-binding peptides have the same
motif as that defined by pool sequencing of the peptides
bound by members of the HLA-B22 family - namely,
proline at position 2 and alanine at position 9. More
importantly, it suggests that certain peptides bound by
HLA-B*0702 will also bind HLA-B22 allotypes.
The hypothesis of overlap between the repertoires of
bound peptides was proven correct by the isolation of
identical endogenously bound peptides from different
HLA-B allotypes (Table 3). Four such peptides were
identified, and for three of them, analysis of the data-base
of protein sequences revealed a cellular protein from
which the peptide was likely to have been derived. One
peptide, which is identical to part of the HLA-DP signal
sequence, was found to be bound by HLA-B*0702,
HLA-B*5501, HLA-B*5502 and HLA-B*5601. The
second peptide, identical to residues 37-45 of -actin
[24], was isolated from HLA-B*0702 and HLA-B*5502.
Both HLA-B*5502 and HLA-B*5601 bind the third
peptide, which has a sequence identical to residues 6-14
of the LMP2 protein [25]. The fourth peptide, having
the sequence Ala-Pro-Arg-Gln-Pro-Gly-Leu-Met-Ala,
was present in the peptides extracted from HLA-B*5501,
HLA-B*5502 and B*5601, and was isolated from
HLA-B*0702 by Engelhard et al. [26]. Of the nine
different peptide sequences defined in this study, four
were isolated from more than one allotype, suggesting
considerable overlap in the endogenous peptides bound
by these HLA-B allotypes.
For five of the individual peptides sequenced, a human
protein was identified from which they were likely to
have been derived. These were all intracellular proteins,
consistent with accumulated observations that class I
molecules bind peptides derived from intracellular pro-
teins (reviewed in [1]). The major pathway for generating
peptides that are then bound by class I molecules involves
partial protein degradation in the cytoplasm, followed by
transport of peptides into the endoplasmic reticulum,
where they bind newly synthesized class I molecules. Of
particular interest, a peptide bound by both HLA-
B*5502 and HLA-B*5601 has an exact match to LMP2.
LMP2 is an MHC-encoded component of the proteo-
lytic complex known as the proteasome, which is impli-
cated in the generation of class I-bound peptides. Mouse
LMP2 is synthesized as a precursor, from which the
amino-terminal sequence is cleaved prior to incorpora-
tion of LMP2 into proteasomes [27,28]. The class I-
bound peptide from human LMP2 derives from a
sequence homologous to part of this cleaved region, sug-
gesting that human LMP2 undergoes similar post-transla-
tional processing. Peptides that are generated by cleavage
of signal sequences from proteins following their trans-
location into the endoplasmic reticulum represent a sec-
ond source of class I-binding peptides [29]. Isolation of
the HLA-DP signal sequence peptide from four allotypes
emphasizes the contribution of this pathway to the
bound-peptide repertoire.
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Members of the HLA-B22 family are functionally similar
HLA-B*5401, HLA-B*5501, HLA-B*5502 and HLA-
B*5601 have very similar peptide-binding specificities.
Analysis of the peptide pools eluted from these HLA-B22
subtypes showed that differences were confined to minor
variation in amino-acid signals at non-anchor positions
4-8, along with differential amino-acid selection at the
secondary anchor position, at the amino terminus of
peptides bound by HLA-B*5401. Similarity in peptide
binding by these four allotypes correlates with relatedness
of their heavy chains, which differ at only 1-3 amino
acids (Fig. 1). The closely related subtypes HLA-B*4402
and HLA-B*4403, which differ only by a single amino-
acid substitution in the peptide-binding site, also have
markedly similar peptide-binding motifs [30]. Despite
apparent equivalence, a strong alloreactive cytotoxic
T-cell response is generated between these two allotypes,
both in vitro [31] and in vivo upon bone marrow trans-
plantation [32]. The ability of cytotoxic T cells to distin-
guish between HLA-B*4402 and HLA-B*4403 is
thought to reflect formation of distinct conformational
epitopes by the same peptides presented in the context of
different class I molecules [30].
To test whether the functional impact of polymorphism
within the HLA-B22 family is also manifest at the level
of cytotoxic T-cell recognition, we compared the capac-
ity of alloreactive cytotoxic T cells raised against either
HLA-B*5401 or HLA-B*5501 (which differ at three
amino acids) to cross-react with the other allotype.
Various dilutions of peripheral blood lymphocytes were
stimulated with cells expressing either HLA-B*5401 or
HLA-B*5501. Cytotoxic T-cell specificity was assessed
by splitting individual cultures and testing equivalent
aliquots for reactivity against transfected target cells
expressing either HLA-B*5401, HLA-B*5501 or HLA-
B*2705 as the only HLA-A, -B or -C molecules. At
limiting dilution, cultures which are reactive predomi-
nantly reflect the response of a single cytotoxic T-cell
clone. Cross-reactivity was therefore assessed by compar-
ing the responses of individual cultures established at
limiting dilutions to the panel of target cells. Cytotoxic T
cells were found to exhibit significant cross-reactivity
between HLA-B*5401 and HLA-B*5501. Results from
donor 1 showed that 48 % (12/25) of cytotoxic T cells
stimulated by HLA-B*5401 also showed cross-reactivity
with HLA-B*5501, with 75 % of these recognizing both
allotypes equally (Fig. 3a). Similarly, for the cytotoxic T
cells stimulated with HLA-B*5501, 73.7 % (14/19) were
cross-reactive with HLA-B*5401 and 85.7 % of these
recognized both allotypes equally (Fig. 3b). In contrast,
there was no cross-recognition of alloreactive cytotoxic
T cells raised against HLA-B*5401 or HLA-B*5501 with
the more divergent allotype HLA-B*2705 (data not
shown). Similar results were obtained with peripheral
blood lymphocytes from a second donor of different class
I haplotype (data not shown). This result demonstrates
the functional similarity of HLA-B*5401 and HLA-
B*5501, as many alloreactive cytotoxic T cells fail to
distinguish between these two HLA-B22 subtypes.
Discussion
Many class I allotypes prefer peptides with proline at
position 2
In human populations, HLA-B is the most polymorphic
of the MHC class I gene loci, and HLA-B alleles provide
the clearest associations of class I with disease outcome
[33,34]. Of the 97 HLA-B alleles defined to date, almost
every pair of alleles can be distinguished by at least one
residue of the peptide-binding site, suggesting that new
HLA-B alleles are selected for novelty in their peptide-
binding specificity.
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Fig. 3. Alloreactive cytotoxic T cells exhibit cross-reactive recog-
nition of HLA-B'5401 and HLA-B*5501. Peripheral blood lym-
phocytes from donor 1 were stimulated with either (a) the LKT-3
(HLA-A24, B*5401, Cw3) or (b) VEN (HLA-A3,A31, B18,B*5501,
Cw3,Cw5) cell lines. Cross-reactivity was assessed by correlating
the responses of individual positive wells at limiting dilutions to
transfected 721.221 target cells expressing either HLA-B*5401 or
HLA-B*5501 as the only HLA-A, -B or -C molecules.
We define here the peptide-binding specificity of six
HLA-B allotypes that differ by 1-9 residues of their pep-
tide-binding sites but have an identical sequence in their
ctl helices. Despite their sequence differences, all six
allotypes exhibit a strong preference for binding peptides
with proline at position 2. Indeed, their peptide-binding
motifs are sufficiently similar that HLA-B*0702 and
members of the HLA-B22 family can bind identical pep-
tides. This finding is the first demonstration that identical
endogenously bound peptides can be isolated from a
number of different allotypes. Previous observations of
individual peptides binding more than one allotype have
been confined in vitro to assays using synthetic peptides
[12,14-18]. Our study shows that overlap in the reper-
toires of peptides bound by class I allotypes occurs in
vivo. Of note, isolation from four allotypes of a peptide
identical to part of the HLA-DP signal sequence high-
lights the significant role that post-translational process-
ing of proteins has in the supply of endogenous peptides
for binding to class I molecules.
Combining our results with those of previous analyses
reveals that proline at position 2 is a common feature of
the peptide-binding motif of class I molecules. In addi-
tion to the six allotypes examined in this study, a proline
anchor at position 2 has been reported for HLA-
B*5301 [17], HLA-B*3501 [17,35], HLA-B*5101
[17,36] and mouse H-2Ld [37]. Moreover HLA-B*0801
exhibits a preference for proline at position 2, although
it does not constitute the dominant specificity [16], and
several HLA-C allotypes also accommodate peptides
with this motif [38].
The shared preference for peptides containing proline at
position 2 among allotypes with divergent sequences
demonstrates that not all polymorphisms confer drastic
change on the repertoire of bound peptides. Evidently,
certain key features of the peptide-binding sites are
shared. To facilitate structural analysis and correlations
with the function of class I molecules, the peptide-bind-
ing site can be delineated into six specificity pockets,
A-F, (Fig. 4) [7]. The B pocket accommodates the dom-
inant anchor residue at position 2 of peptides bound in
the crystal structures of HLA-A*0201 and HLA-B*2705
[7,39], and common to all allotypes that bind peptides
with proline at position 2 is a large bulky aromatic
residue within the B pocket (Table 4). In the six allo-
types we examined, the aromatic residue of the B pocket
is provided by tyrosine at position 67. Although no crys-
tal structures are available for allotypes with specificity
for proline-containing peptides, Madden et al. [8] specu-
lated that the presence of an aromatic residue at position
67 would substantially fill the position-2-binding
pocket, creating a small hydrophobic subsite. Molecular
modelling of HLA-B*0702 shows that the proline side
chain can fit in such a B pocket [40].
The aromatic residue that appears to confer selectivity for
proline varies between tyrosine and phenylalanine
according to the allotype, as does its location (position 45
or 67), but the functional effect is the same. So far, all
allotypes with an aromatic amino acid at position 45 or
67 have been shown to bind peptides with proline at
position 2. On the basis of this empirical correlation
between peptide anchor residues and pocket structure,
we predict an additional 20 of the currently defined
HLA-B alleles (B*0703-4, B*0802, B*4201, B*1508,
B*1511, B*4601, B*3502-8, B*5102-4, B*7801,
B*5602, B*5901) encode proteins that also bind peptides
with proline at position 2.
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Fig. 4. Schematic representation of the
three-dimensional structure of the al
and a2 domains of the class I HLA mol-
ecule, as viewed from above. Locations
of the six pockets A-F of the peptide-
binding site are shown. Residues that
contribute to formation of the pockets
are shaded: red for the A pocket; blue
for B; green for C; yellow for D; purple
for E; orange for F. Residues that exhibit
polymorphism among the allotypes
examined in this study are indicated by
numbers.
The advantage of binding proline-containing peptides
That class I allotypes of divergent sequence have the same
preference for binding peptides with proline at position 2
is good evidence for independent or convergent evolu-
tion of this specificity. In turn, this observation suggests
that there has been a selective advantage for class I mol-
ecules to bind proline-containing peptides. We speculate
that this advantage is related to the intracellular supply of
peptides. Peptide-binding facilitates cell-surface expres-
sion of class I molecules by promoting assembly of stable,
properly folded complexes [41-44]. Evidence suggests
that peptide supply is a limiting factor in the assembly of
class I molecules [45]. Under such circumstances, it
might be expected that class I peptide-binding sites
would evolve to exploit the most abundant populations
of available peptides.
The peptides bound by class I molecules are derived
mainly from intracellular proteins that have undergone
partial proteolysis in the cytoplasm. An endopeptidase
complex, the proteasome, is believed to contribute to
peptide generation [46] and has activities similar to tryp-
sin, chymotrypsin and peptidylglutamyl-peptide hydrolase
(reviewed in [47,48]). Because of proline's unique cyclic
imino structure, peptide bonds involving proline are rela-
tively resistant to cleavage by many exopeptidases and
endopeptidases, including amino- and carboxy-peptidases,
trypsin, chymotrypsin, and signal peptidases [49,50]. As a
consequence, the cellular pool of potential class I-binding
peptides may be enriched in proline-containing peptides.
Adaptation to the available supply of endogenous peptides
could increase the effectiveness of class I molecules in
their selection and stimulation of lymphocyte receptors.
Evolution of peptide-binding specificity in the HLA-B22 family
Formation of new HLA-B alleles most frequently
involves gene recombination events that replace a short
segment of one allele with the homologous region of
another [19]. Typically these exchanges produce two or
three amino-acid substitutions in the peptide-binding
site. Many families comprising up to 16 alleles that differ
in this way have been described [21].
In this study, the peptide-binding specificities of four
subtypes from the HLA-B22 family were analyzed. The
subtypes appear to be evolutionarily related by simple
recombinations and differ by 1-3 substitutions in their
peptide-binding sites [20]. Despite these differences, the
repertoires of peptides bound by the HLA-B22 subtypes
are remarkably similar. The peptide-binding motifs are
very similar, and identical peptides are present in the
peptide pools isolated from different HLA-B22 subtypes.
Of note, the main difference observed was differential
selection of amino acids at position 1 (a secondary
anchor) of peptides bound by HLA-B*5401. This sub-
type appears to have been generated by a rare inter-locus
gene recombination involving HLA-B*5502 and an
HLA-C allele [20]. The result is that HLA-B*5401 has a
combination of residues otherwise unique to HLA-C
allotypes, namely glycine at position 45 and valine at 52.
Despite this difference, however, comparison of allo-
reactive T cells raised against HLA-B*5401 and HLA-
B*5501 showed that many cannot differentiate between
these two subtypes.
Evident from these results is that the recombination
events that generated the HLA-B22 subtypes did not
produce major alterations in the types of peptides bound
or their presentation to cytotoxic T cells. If differences
exist, they are subtle, and their identification will require
more extensive analysis of individual peptides and
cytotoxic T-cell clones. If the subtypic similarities seen in
the HLA-B22 family are reiterated in other class I HLA
families, there are significant medical implications. In
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clinical transplantation, for example, the capacity of
subtypic differences to stimulate either graft rejection
or graft-versus-host disease has been questioned [51].
Certain subtypic differences are known to stimulate allo-
reactions [31,52-54], but that may not be true for all
such differences and identification of those differences
that do not will increase the probability of matching
unrelated donors and recipients for transplantation.
Conclusions
Despite multiple differences at residues comprising the
peptide-binding site, a group of class I HLA-B allotypes
were found to have such similar peptide-binding speci-
ficities that they can bind identical peptides. Oir study is
the first to describe isolation of identical endogenously
bound peptides from several class I allotypes, thereby
demonstrating in vivo the relevance of overlapping pep-
tide repertoires. The finding that groups of allotypes bind
the same peptides has the potential to reduce the com-
plexity of peptide-based vaccines aimed at stimulating
cytotoxic T-cell responses against intracellular pathogens.
This observation also suggests that future attempts to cor-
relate disease with class I HLA type on the basis of pep-
tide-binding specificities may reveal associations not seen
in correlations made using individual allotypes.
Materials and methods
Cell lines and antibodies
Human Epstein-Barr virus (EBV)-transformed B lymphoblas-
toid cell lines used as the source for HLA class I protein were:
JY (HLA-A2.1, B*0702); LKT-3 (HLA-A24, B*5401, Cw3);
VEN (HLA-A3, A31, B18, B*5501, Cw3, Cw5); APA (HLA-
A9.3, All Bw75, B*5502, Cw3); VOO (HLA-AI, A3, B8
B*5601, Cwl) and W7079 (HLA-A2, B*6701, B*4001,
Cw7, Cw3). Cells were cultured in roller bottles in RPMI
1640 medium supplemented with 10 % bovine calf serum
(HyClone, Logan, Utah), 2 mM L-glutamine, 100 U ml-1
penicillin, and 100 Ipg ml-I streptomycin. Batches of 10-20 1 of
cells (approximately 1010 cells) were harvested by centrifuga-
tion, washed once with phosphate-buffered saline and the cell
pellets and frozen at -80 °C before purification of the class I
proteins. An IgG2a switch variant of the mouse monoclonal
antibody MEI [55] was used to purify the allotypes indicated
in bold. The MEI antibody exhibits specificity for HLA-B*7,
B*27, B*42, B*54, B*55, B*56 [23,55], HLA-B*6701 [22]
and HLA-B*7301 [56].
Class I purification and isolation, and separation of bound
peptides
Cells were lysed in 20 mM Tris-HCI pH 8, 150 mM NaCl
buffer containing 1.5 % nonidet P-40 (NP-40), 2 mM phenyl-
methylsulphonyl fluoride, 100 Rm iodoacetamide, 5 g ml-'
aprotinin, 5 g ml-' leupeptin, 5 zg ml-1 pepstatin A, 1 mM
EDTA and 0.2 % sodium azide. Class I proteins were purified
from cell lysates by immunoaffinity chromatography using the
monoclonal antibody ME1. Antibody was purified using affi-
gel protein A agarose (BioRad, Richmond, California), and
then covalently coupled to protein A Sepharose (Pharmacia
LKB, Uppsaala, Sweden) using dimethyl pimelimidate-2 HCI.
Antibody was coupled at 5 mg ml-1 beads (wet volume) and
10 mg antibody in total was used for purification from lysates
made from 101° cells.
The lysate was passed initially through a column containing
2ml protein A Sepharose at a flow rate of 0.5 ml min- 1 to
remove components that adhere non-specifically to the matrix.
This was followed by overnight incubation of the lysate with
the affinity matrix using slow rotation. These, and all subse-
quent steps in the purification procedure, were performed at
4 C. The affinity matrix was placed in a column and the lysate
applied at a flow rate of 0.5 ml min- 1. After sample application,
the column was washed consecutively with 20 column vol-
umes each of the following three buffers: 20 mM Tris-HCI
pH 8, 150 mM NaCI, 1 % NP-40; 100 mM Tris-HCI pH 8,
0.5 M NaCI; and 100 mM Tris-HCI pH 8. Class I protein was
then eluted with 10 ml 0.2 N acetic acid (pH 2.7) and col-
lected as I mil fractions. Protein purity and concentration were
assessed by SDS-polyacrylamide gel electrophoresis.
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Fractions containing class I protein were made to 10 % acetic
acid and incubated at 75 C for 15 min to denature class I
complexes and release bound peptides. The mixture was
cooled to room temperature and the peptides separated from
denatured protein by ultrafiltration using a Centricon 3 filtra-
tion unit (3 000 Dalton cut-off membrane; Amicon, Beverly,
Massachusetts). The peptide-containing filtrate was concen-
trated by vacuum centrifugation to a volume of 100 pil.
Peptides were separated on a C18 reverse-phase column
(2.1 mmn internal diameter x 15(0 mm length; Vydac) using an
HPLC (model 140B solvent delivery system; Applied Bio-
systems, Foster City, California). Peptide mixtures were loaded
in 10 % acetic acid and the column eluted using gradients
made from 0.06 % trifluoroacetic acid in water (buffer A) and
0.05 % trifluoroacetic acid in 80 % acetonitrile with water
(buffer B) at a flow rate of 150 I min 1. A gradient starting
from 5 % buffer B, rising to 55 % B at 100 minutes and then
increasing to 95 % B at 120 minutes, was used. The column
eluate was monitored spectrophotometrically for absorbance at
214 nm (Applied Biosystems 785A absorbance detector) and
individual peaks of absorbance were collected manually in
1.5 mnl microfuge tubes. Each fraction was quickly frozen on
dry ice and stored at -70 C.
Automated Edman degradation sequencing
Peptide-binding motifs of class I molecules were deduced by
sequencing mixtures of eluted peptides - 'pool sequencing'.
This approach is based on the assumption that a dominant,'sig-
nal for an amino acid at a particular cycle in the sequencing
reaction indicates the presence of that amino acid at that posi-
tion in a majority of the peptides. HPLC fractions collected at
7-40 % buffer B in the gradient were pooled, concentrated by
vacuum centrifugation, and subjected to amino-acid sequence
analysis on an Applied Biosystems model 476A automated pro-
tein sequencer operated in gas-phase mode. The results were
analyzed using model 610A data analysis software from Applied
Biosystems. As cysteine was not modified, it was not de-
tectable; in some cases, tryptophan was not assigned as it
co-elutes with a byproduct of the sequencing reaction.
Interpretation of the results of the peptide pool sequencing was
performed using raw data. Values below pmole were
ignored. Amino acids obtained at each cycle of the sequencing
reaction were grouped into the following categories, with
assignments listed in order of decreasing yields of the PTH
amino acids: dominant, yield of a single amino acid increases
several fold over that in the previous cycle; strong, amino acids
having a more than 2-fold increase over that obtained in the
previous cycle; weak, residues with an increase of 1.5-2-fold
over the previous cycle. Because comparison with previous
cycles was impossible for cycle 1, analysis of this position was
performed by calculation of percent molar yields for each
amino acid.
To characterize individual peptides, well-resolved peaks from
separation of the peptide pools were subjected to analysis by
Edman degradation sequencing. To confirm the sequences
obtained, small aliquots (10 %) of the fractions were analyzed
by mass spectrometry to obtain molecular weight measure-
ments. In some cases, further verification was obtained from
partial sequences obtained by tandem mass spectrometry. A
search of the GenBank data-base using the Wisconsin Genetics
Computer Group programs [57] and a VAX 4000-90 com-
puter was performed to identify proteins from which peptides
sequenced could be derived.
Mass spectrometry
Molecular weights of individual peptides were measured by
electrospray ionization mass spectrometry on a SCIEX API
III triple quadrupole mass spectrometer (SCIEX, Thornhill,
Canada). Peptides were monitored by capillary HPLC-mass
spectrometry using the same buffers and gradient as described
above, at a flow rate of 2 I min- 1. The column (180 .m
internal diameter x 15 cm length) was packed with 5 Rm par-
ticle size C18 matrix (LC Packings, San Francisco, Cali-
fornia). The quadrupole mass spectrometer was operated with
the ionspray articulated nebulizer at 4600 V, the interface
plate at 600 V, and the orifice at a range of 80-120 V. Data
were collected every 0.1-0.25 u with the quadrupole scan-
ning from 600-2200 u in 32 seconds. Mass resolution was set
to 1000 m/Am, allowing assignment of singly charged and
doubly charged peptide ions. Collision-induced dissociation
experiments used argon as the collision gas at 50-60 eV to
fragment peptides.
Assessment of cytotoxic T-cell cross-reactivity by
split-well analysis at limiting dilution
Limiting dilution experiments were conducted as described
previously [58]. Human peripheral blood lymphocytes were
obtained by Ficoll separation of heparinized blood from
healthy donors and cryopreserved until required. Donor class I
alleles were characterized by DNA sequence analysis accord-
ing to the protocol described by Domena et a. [59] as: donor
1: -- HLA-A*0101, -A*0301; -B*0702, B*1501; -Cw0302--
; donor 2: -- HLA-A*0201, -A*0301, -B*40012, -B*5001,
-Cw0602--. Donor peripheral blood lymphocytes were
thawed and plated at 0.6 x 103, 1.2 x 103, 2.5 x 103 and 5
x 103 cells per well (24 replicates per concentration) into
round-bottom microtitre wells in RPMI 1640 medium sup-
plemented with 10 % fetal bovine serum (HyClone, Logan,
Utah), 2 mM L-glutamine, 5 x 10- 5 M ,B-mercaptoethanol,
100 U ml- I penicillin, 100 Rg ml- streptomycin and 5 U
recombinant interleukin-2 per ml. Constant numbers (5 x
104) of irradiated (2000 rad) stimulator cells were added to
each well and the plates incubated at 37 C in a humidified
atmosphere containing 5 % CO2 . After 5 days, each well was
split and equal aliquots incubated with a panel of 5 lCr labelled
target cells ( x 103) for 4 hours at 37 C. Supernatants were
harvested and assayed for 51Cr radioactivity using a gamma
counter. Wells in which cytotoxic T-cell lysis of target cells
resulted in specific release of > 10 % of the radioactivity were
considered positive. Cytotoxic T-cell cross-reactivity was
assessed by correlating responses of individual positive wells at
limiting dilutions to the panel of target cells.
Cells used as stimulators were EBV-transformed B lympho-
blastoid cell lines LKT-3 (HLA-A24, B5401, Cw3) and
VEN (HLA-A3,A31, B18, B*5501, Cw3,CwS). The HLA-
A, -B and -C negative EBV-transformed B lymphoblastoid
cell line 721.221 [60] transfected with HLA-B*5401,
HLA-B*5501 or HLA-B*2705, as described by Litwin et al.
[61], were used as targets. On the day of assay, stable and
comparable expression of the transfected class I alleles was
confirmed by immunofluorescent staining and flow cyto-
metric analysis.
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